Searchable abstracts of presentations at key conferences in endocrinology

ea0022p562 | Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Assessment of biochemical control of acromegaly during treatment with somatostatin analogues: is there still a role for glucose oral load?

Carzaniga Chiara , Scacchi Massimo , Vitale Giovanni , Fatti Maria Letizia , Giraldi Francesca Pecori , Andrioli Massimiliano , Cavagnini Francesco

Biochemical control of acromegaly is currently defined by the achievement of GH suppression after oral glucose tolerance test (OGTT) and of normal age- and gender-matched IGF1 levels. OGTT is believed to inhibit somatotropin secretion by enhancing central somatostatinergic tone; thus, the use of this test in evaluating biochemical control in acromegalic patients on somatostatin analogues (SSA) is questionable. To gain further insights into this topic, we analyzed basal and nad...

ea0022p561 | Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

The diagnosis of GH deficiency in obese patients: what help from pharmacological blockade of lipolysis?

Orsini Federica , Cattaneo Agnese , Grasso Alice , Filippini Barbara , Fatti Maria Letizia , Moro Mirella , Scacchi Massimo , Cavagnini Francesco

The diagnostic approach to GH deficiency (GHD) in obese patients is complicated by the reduced spontaneous and stimulated GH secretion associated with overweight. A GH response to GHRH+arginine lower than 4.2 μg/l is currently considered indicative of GHD in obesity (Corneli et al., Eur J Endocrinol 2005). Aim of the study was to verify the diagnostic validity of this cut-off value by investigating the effect of acute pharmacological blockade of lipolysis on...